Oral and Long-Acting Incretins Market Outlook 2026–2034: Market Size, Growth Drivers, Key Players, Strategic Developments & Adoption Forecast for Oral GLP-1 Tablets, Triple Agonists, Amylin Combinations, Monthly Formulations, Pricing Reform and Medicare Coverage — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines how the next generation of incretin therapies — oral GLP-1 tablets, triple agonists, amylin combinations and monthly or long-acting formulations — will reshape obesity, diabetes and cardiometabolic care over the next eight years, after a first generation of weekly injections that made tirzepatide alone a USD 36.5 billion product in 2025. The second generation has arrived in the clinic and on the shelf. Oral Wegovy, semaglutide 25 mg tablets, was approved by the FDA in December 2025 and by the MHRA in June 2026 and the European Commission in July 2026, with 13.6% placebo-adjusted weight loss at 64 weeks in OASIS 4; Eli Lilly's orforglipron, Foundayo, the first small-molecule oral GLP-1, was approved on 1 April 2026 and launched at USD 149 to USD 299 a month through LillyDirect after 11.2% weight loss in ATTAIN-1 and a 2.2-point A1C reduction against 1.4 for Rybelsus; and Lilly's triple agonist retatrutide reported 25.0% weight loss at 80 weeks in TRIUMPH-1 in May 2026, with filing expected around the end of 2026. Novo Nordisk filed CagriSema, which delivered 20.4% weight loss in REDEFINE 1, with the FDA in December 2025 and is taking amycretin into phase 3, while Amgen's monthly MariTide heads for 2027 readouts. The economics changed in November 2025 when the White House, Lilly and Novo agreed USD 245 Medicare and Medicaid prices, USD 350 cash prices, USD 149 oral starting doses and the first Medicare coverage of obesity drugs at a USD 50 copay, and Lilly guided to USD 80–83 billion of 2026 revenue. The brief maps the technology, its indicative market size and forecast, the factors behind its growth, the developments of the last 24 months, the key players operating in the space and the adoption trajectory to 2034.

It is a focused 100-page decision brief for pharmaceutical companies, payers and pharmacy benefit managers, health systems and employers, device and digital health companies, manufacturers and investors. It presents an indicative trajectory rather than a segmented market model. Its purpose is to identify which next-generation products win which patients, how oral delivery, higher efficacy and lower prices change the market's shape, and who captures the resulting value.

Incretin therapies mimic gut hormones that regulate appetite and blood sugar. First-generation GLP-1 and GLP-1/GIP agonists — semaglutide and tirzepatide — are weekly peptide injections. The next generation changes the molecule, the route or the interval. Oral semaglutide at 25 mg uses an absorption enhancer to deliver the peptide by tablet, giving 13.6% placebo-adjusted weight loss at 64 weeks; orforglipron is a non-peptide small molecule that binds the GLP-1 receptor, can be made by conventional chemical synthesis at scale and taken without food restrictions, giving 11.2% weight loss in ATTAIN-1 and 9.6% in ATTAIN-2 at 72 weeks and a 2.2-point A1C reduction. Retatrutide adds glucagon receptor activity to GLP-1 and GIP and produced 25.0% weight loss at 80 weeks, 28.3% on the efficacy estimand and about 30% at 104 weeks in a subgroup. CagriSema pairs semaglutide with the amylin analogue cagrilintide for 20.4% at 68 weeks; amycretin combines both activities in one molecule, with 24.3% at 36 weeks in an early trial; MariTide, an antibody-peptide conjugate, is dosed monthly or less often with 12.3–16.2% at 52 weeks in phase 2.

Economics now define the market. Tirzepatide sold USD 36.5 billion in 2025 and Lilly guided to USD 80–83 billion of 2026 revenue; the November 2025 White House agreements set USD 245 Medicare and Medicaid prices, USD 350 cash prices on TrumpRx, USD 149 starting prices for oral GLP-1s and the first Medicare coverage of obesity drugs at a USD 50 copay, with Novo cutting U.S. list prices by up to 70% and receiving a three-year tariff exemption. Orals widen the funnel — Foundayo at USD 149 to USD 299 a month reaches patients who will not inject or cannot pay — while high-efficacy injectables serve patients with the greatest medical need. Generic semaglutide in India, Canada and South America sets a price floor outside the United States.

The constraints are tolerability, durability, manufacturing and payer capacity. Gastrointestinal effects limit dose escalation; weight regain after stopping raises questions about maintenance regimens and lean-mass preservation; oral peptides need absorption enhancers and small molecules need large-scale chemical manufacturing; and coverage of tens of millions of patients, even at USD 245, strains Medicare, Medicaid and employer budgets. The decade's question is how the market splits between cheaper orals for the many and higher-efficacy injectables for the few.

The oral and long-acting incretins market — sales of oral GLP-1s, multi-agonists, amylin combinations and monthly or long-acting incretin products, excluding first-generation weekly semaglutide and tirzepatide injectables — is estimated at USD 4–6 billion in 2026, led by the first year of oral Wegovy and Foundayo in the United States and early launches in the United Kingdom and Europe. Meticulous Next™ expects it to reach USD 70–90 billion by 2034, an indicative CAGR of 40–45%. Growth is driven by oral GLP-1s becoming the entry therapy for obesity and type 2 diabetes at USD 149–299 price points, by Medicare and payer coverage from 2026, by retatrutide and CagriSema approvals in 2027 for high-efficacy use, by amycretin, MariTide and maintenance regimens from 2028 to 2030, by cardiometabolic indications beyond weight and by international launches where generics set price floors. The forecast is sensitive to pricing reform, coverage decisions and manufacturing scale. The United States leads on approvals, pricing reform and volume; the United Kingdom and European Union follow with 2026 approvals; India, Canada and South America are generic semaglutide markets; China and Japan launch orals and multi-agonists on their own timelines.

The base case assumes oral GLP-1s reach mass adoption in 2026–2027, retatrutide and CagriSema are approved in 2027 and Medicare coverage is sustained at agreed prices. An accelerated case adds rapid employer and national coverage, early amycretin and MariTide approvals and new cardiometabolic indications, bringing the inflection to 2027 and lifting the 2034 value to the top of the range. A delayed case assumes coverage retrenchment, tolerability or durability concerns for triple agonists and manufacturing limits, pushing the inflection to 2030 and leaving first-generation injectables dominant longer.

Growth drivers

• Oral delivery at low prices: Foundayo at USD 149–299 and oral Wegovy at USD 149–299 for patients who will not inject or cannot pay.
• Higher efficacy: retatrutide's 25% and CagriSema's 20% weight loss for patients with the greatest need.
• Coverage and pricing reform: USD 245 Medicare and Medicaid prices, USD 50 copays and the first Medicare obesity coverage.
• Commercial proof: tirzepatide USD 36.5 billion in 2025 and Lilly 2026 guidance of USD 80–83 billion.

Enablers

• Small-molecule oral GLP-1 chemistry that scales by conventional synthesis without food restrictions.
• Direct-to-patient channels such as LillyDirect and TrumpRx.
• Manufacturing investment in peptides, orals and devices by Lilly and Novo.
• Expanding cardiometabolic evidence across heart, kidney, liver and sleep indications.

Restraints and barriers

• Gastrointestinal tolerability, weight regain after stopping and lean-mass loss.
• Payer and government budget limits even at reduced prices.
• Manufacturing scale for oral peptides and small molecules at global demand.
• Generic and compounded competition outside and inside the United States.

Five converging forces will determine how fast, and how far, next-generation incretins reshape metabolic care: (1) oral delivery at low price points; (2) higher-efficacy multi-agonists and combinations; (3) pricing reform and coverage; (4) manufacturing and channel scale; and (5) expanding cardiometabolic indications and maintenance regimens. The brief assesses each force for direction, speed and confidence.

The key players operating in oral and long-acting incretins include Eli Lilly and Company, Novo Nordisk A/S, Amgen Inc., Pfizer Inc., AstraZeneca PLC, Roche Holding AG (Carmot Therapeutics), Boehringer Ingelheim International GmbH, Zealand Pharma A/S, Structure Therapeutics, Inc., Viking Therapeutics, Inc., Metsera, Inc., Terns Pharmaceuticals, Inc., Altimmune, Inc., Skye Bioscience, Inc., Innovent Biologics, Inc., Hengrui Pharmaceuticals Co., Ltd., Sciwind Biosciences Co., Ltd., Hansoh Pharmaceutical Group Company Limited, Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Limited, Apotex Inc., Sandoz Group AG, Biocon Limited, Zydus Lifesciences Limited, Cipla Limited, Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd., CVS Health Corporation, Cigna Group (Express Scripts), UnitedHealth Group Incorporated (Optum Rx), Hims & Hers Health, Inc., Ro, WeightWatchers (WW International, Inc.), Omada Health, Inc., Virta Health Corp., Catalent, Inc., Thermo Fisher Scientific Inc. and Ypsomed Holding AG. The brief profiles representative players in each archetype and assesses which are positioned to lead next-generation metabolic care.

The competitive landscape is forming around six archetypes. Franchise leaders with oral and multi-agonist portfolios. Large pharma followers with phase 2–3 orals and combinations. Biotechs with differentiated mechanisms. Generic and biosimilar manufacturers. Payers, pharmacy benefit managers and government programmes. Direct-to-patient, digital care and manufacturing partners. Competitive intensity is high in 2026 and is expected to intensify as orals, triple agonists and generics converge through 2028.

Where value migrates.

In 2026 value sits in first-generation weekly injectables and the first oral launches at USD 149–299 under new Medicare coverage. By 2028 it moves to orals as entry therapy for most patients, retatrutide and CagriSema for high-need patients, direct-to-patient channels and payer-negotiated volume. By 2034 it settles in Lilly and Novo's oral and multi-agonist franchises, differentiated followers with monthly and combination products, pharmacy and digital channels, manufacturers and digital care platforms, while first-generation injectables and generics serve price-sensitive segments.

Capital is concentrated in the two leaders — tirzepatide USD 36.5 billion in 2025, Lilly guiding to USD 80–83 billion in 2026, Novo cutting prices by up to 70% to defend volume — and in manufacturing, direct-to-patient channels and a cohort of followers from Amgen's monthly MariTide to Chinese oral and dual-agonist developers. Clinical output is dense: OASIS 4, ATTAIN-1 and -2, TRIUMPH-1, REDEFINE 1 and 2 and MariTide phase 2 within eighteen months. Patent and research activity is concentrated in oral small-molecule GLP-1 chemistry, triple and amylin agonism, extended-release and monthly formulations, muscle preservation and maintenance regimens. The brief tracks four indicators: oral GLP-1 prescription volumes, retatrutide and CagriSema approval decisions, Medicare and employer coverage uptake and price levels including generics.

The United States leads on approvals, pricing reform, Medicare coverage and volume; the United Kingdom and European Union follow with 2026 oral approvals; India, Canada and South America are generic semaglutide markets; China and Japan launch domestic orals and multi-agonists. Obesity and type 2 diabetes lead; cardiometabolic, sleep, liver and kidney indications follow.